Papers

To describe the historical baseline landscape of cardiovascular drug post-approval activity, including the number and timing of post-approval clinical trials and approved indications. The US Inflation Reduction Act of 2022 (IRA) Drug Price Negotiation Program (DPNP) and its Maximum Fair Prices (MFPs) will affect incentives for investment in post-approval activity such as clinical trials for […]

Alternative funding programs come at a significant cost to patients and the health care system.

The Extra Help program provides financial assistance to low-income and limited-income people enrolled in Medicare Part D prescription drug coverage.

A new Avalere white paper raises important considerations on potential added lifecycle pressures for sponsors of cardiovascular disease products.

Cardiovascular disease has long been the number one overall cause of death in the United States. Forecasts indicate the situation will worsen.

Over the next decade, about 25 million U.S. adults will develop hypertension — even though the potentially deadly disease is both easily diagnosed and treatable.

PACH wrote a letter urging CMS to support a uniform set of quality measures, including those specific to cholesterol testing or management, where significant disparities exist.

Many people with hypertrophic cardiomyopathy often go undiagnosed. This is because the symptoms of HCM aren’t always immediately recognized as indicators of a cardiac condition.

Nearly one in every 250 people have HCM, but a large percentage of patients go undiagnosed because symptoms mimic other non-cardiac related diseases.

Arizona’s rate of heart disease is higher than the national average. Yet insurers are more likely to reject Arizonans’ prescriptions for cholesterol-lowering medication.

Oklahoma’s rate of heart disease is higher than the national average. Yet insurers are more likely to reject Oklahomans’ prescriptions for cholesterol-lowering medication.

Texas’ rate of heart disease is higher than the national average. Yet insurers are more likely to reject Texans’ prescriptions for cholesterol-lowering medication.